activity of these intracellular enzymes results in increases in methylmalonic acid (MMA) and homocysteine concentrations. 1 heteromeric, multiligand, endocytic receptor, consisting of 2 proteins, AMN and CUBN. 2 In people, mutations in either the AMN or CUBN gene lead to selective Cbl malabsorption known as Imerslund-Gräs-beck syndrome (IGS). 3, 4 In dogs, selective intestinal Cbl malabsorption, comparable to IGS in humans, has been described in Australian
Shepherds, 5, 6 Beagles, [7] [8] [9] [10] [11] [12] [13] Border Collies [14] [15] [16] [17] , and Giant Schnauzers. 18 It is an autosomal recessive trait caused by 2 distinct AMN mutations in Giant Schnauzers 18 and Australian Shepherds, 6 and our group and others recently identified 2 independent CUBN mutations in Border Collies 19, 20 and Beagles. 10, 21 The condition is lethal in affected dogs unless detected and treated appropriately. [9] [10] [11] 16, 18 Supplementation with adequate amounts of Cbl leads to rapid and complete clinical remission when Cbl is administered sufficiently early in the course of disease, and the long-term prognosis is excellent with adequate lifelong treatment. 6, [8] [9] [10] 12, 13 To date, all reported treatments in dogs have consisted of parenteral supplementation to circumvent the underlying cause of the problem (ie, deficient intestinal uptake of the vitamin). However, sporadic reports in human medicine indicate that PO supplementation also leads to normalization of intracellular markers of Cbl deficiency, 22, 23 and it was shown that approximately 1% of free Cbl is absorbed along the entire intestine by passive diffusion without the need for an intact cubam receptor. 24 Although this route of absorption has not been demonstrated in dogs, PO Cbl supplementation recently was determined to effectively increase serum Cbl concentrations in dogs with chronic enteropathies and low serum Cbl concentrations. 25, 26 Our group also has had positive experiences with PO supplementation in older Beagles and Border Collies with IGS that could not tolerate repeated IM injections. These dogs remained clinically healthy and had urine MMA results within reference intervals (RIs) when evaluated sporadically. We recently studied the long-term efficacy of monthly and bimonthly (every 2 months) IM Cbl injections including regular assessment of MMA as a marker of cellular Cbl availability in 6 juvenile Beagles with IGS. 13 All dogs thrived and were clinically healthy, but the prospect of a lifelong need for IM injections prompted owners of 3 dogs to try PO Cbl supplementation. We were able to conduct follow-up assessments of these dogs, which included regular monitoring of markers of intracellular Cbl availability. We hypothesized that a daily supraphysiologic PO dose of 1 mg cyano-Cbl would maintain clinical and metabolic remission in dogs with genetically confirmed IGS.
| MATERIALS AND METHODS

| Animals
The clinical and metabolic health of 3 client-owned purebred Beagles with IGS was monitored for 13 (n = 2) and 8 (n = 1) months. All dogs had been diagnosed with IGS using a commercial genetic test (www.
laboklin.de) for the CUBN mutation and initially had received monthly, followed by bimonthly, IM injections of 1 mg Cbl (VITAMIN B-12
Depot Rotexmedica Injektionslösung) for a period of 15-21 months before being switched to PO supplementation. 13 The age of the dogs at the time of transition to PO supplementation was 31 (dog 1, male, neutered) and 29 (n = 2) months. were collected before PO administration of Cbl that day. All samples were shipped to our clinic on dry ice using a commercial carrier.
| Healthy control dogs
In our previous study on parenteral Cbl supplementation, the RI for urinary MMA concentration was based on urine samples from 28 clinically healthy dogs. 13 In the present study, the results of 2 more healthy dogs with unremarkable laboratory (CBC, serum biochemistry, urinalysis) results and serum Cbl concentrations within RIs were added for a total of 30 clinically healthy dogs. Serum samples from 20 healthy dogs were used for establishing a preliminary RI for serum MMA concentrations in our earlier study, 13 and we were able to strengthen this preliminary RI by adding serum MMA results from an additional 28 healthy dogs with unremarkable clinical and laboratory (see above)
evaluations (n = 48).
| Analyses
Either available serum Cbl concentrations were measured at a commercial veterinary laboratory (www.laboklin.de; n = 1) or samples were frozen and shipped together with urine samples to our laboratory (n = 2). The commercial veterinary laboratory used a chemiluminescence assay for Cbl determination, and the RI was 221-590 pmol/L (B12 ECLIA on Cobas 8000 e602 were used in our laboratory.
Urine and serum MMA concentrations were analyzed at the
Division of Clinical Chemistry of the University Children's Hospital
Zurich according to accredited methods. 28 In brief, the samples were supplemented with an internal standard, precipitated, and analysis was done by ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-TMS) on an Ultimate 3000 XRS UHPLC system (Dionex; Thermo Scientific) with a SCIEX5500 mass spectrometer (SCIEX, Framingham, Massachusetts) using multiple reaction monitor- 
| Statistical analysis
Data were tested for normal distribution using D'Agostino and
Pearson omnibus tests. Urine MMA results of healthy dogs are presented as range and median values. The RI for serum MMA concentration was calculated using the 5th and 95th percentiles.
3 | RESULTS
| Healthy control dogs
Urinary MMA concentrations were not normally distributed in 
| Serum MMA concentrations
In dog 1, serum MMA concentrations were measured at t1 and from t5 to t10. All 7 results were within the RI and ranged from 399 to 919 nmol/L (median, 651 nmol/L; RI, 393-1476 nmol/L). Serum MMA concentration also was measured in dog 3 at t7 and was 642 nmol/L (RI, 393-1476 nmol/L).
| Plasma homocysteine concentrations
In dog 1, plasma homocysteine concentrations at t1-t3 were 21.5, 18.8, and 27.4 μmol/L, respectively, and they ranged from 15 to 23.8 μmol/L (median, 17.7 μmol/L) between t5 and t10. 
| DISCUSSION
14-17
Cobalamin deficiency has been associated with changes in permeability, absorptive function, and histologic appearance of the intestinal mucosa in humans, and mucosal structure and function normalized in these patients after parenteral Cbl treatment. 30 . Please note that dog 1 (pink squares) was treated for an unrelated bacterial skin infection with a 10-day course of cephalexin and amoxicillin starting 2 days after urine sampling at t6
We used a dose of 1 mg cyano-Cbl daily in dogs that weighed approximately 11 kg, which differed from previous studies in which the dose varied from 0.25 to 1 mg cyano-Cbl, depending on body weight. 25, 26 The dogs in our study were known to suffer from complete lack of Cbl absorption in contrast to dogs with enteropathyassociated hypocobalaminemia, and therefore we chose to use a whole tablet (1 mg) per day rather than dividing a tablet. Moreover, experience with a number of older Beagles and Border Collies with IGS from our clinic caseload has shown that this dose works well. In addition, our approach precluded issues with accurate dosing because the manufacturer's recommendation was not to divide coated tablets.
Lastly, adverse effects related to high PO doses of Cbl have not been reported. We generally prefer hydroxo-Cbl for parenteral Cbl supplementation in our hospital because it is the natural form of Cbl and considered the treatment of choice for children with IGS. 4,31-33 Moreover, early studies in dogs showed that hydroxo-Cbl produces more prolonged increases in serum Cbl concentrations when injected IM than injection of equal amounts of cyano-Cbl. 34 In addition, compared to cyano-Cbl, it has been shown that hydroxo-Cbl has increased liver uptake and less rapid urinary excretion in humans. 35 For these reasons, we had also used hydroxo-Cbl in our previous study on the efficacy of parenteral Cbl supplementation in Beagles with IGS. 13 However, at the time of the present study, cyano-Cbl was the only available PO Cbl product in Switzerland.
Although hundreds of IGS cases have been published worldwide in human medicine, only 3 articles [36] [37] [38] have examined the efficacy of PO Cbl supplementation and only 1 article specifically assessed the effect of PO treatment on cellular Cbl status in people. 36 Biweekly PO treatment with 1 mg cyano-Cbl appeared to be a successful maintenance regimen in 14 children with IGS based on clinical signs, hematologic evaluations, and serum Cbl concentrations, 37 whereas 1 mg cyano-Cbl daily for 7 days every month maintained normal clinical health in a teenager with IGS who was monitored for >5 years. 38 However, some abnormalities were identified when cellular Cbl status was assessed in a more recent study. Biweekly PO treatment with 1 mg cyano-Cbl for >5 years resulted in unremarkable hematologic results but did not correct all other markers of Cbl deficiency. 36 Twenty-five percent of patients with congenital Cbl deficiency still had increased concentrations of MMA (n = 4) and homocysteine (n = 1) but unexpectedly had Cbl concentrations within RI, which resulted in discussion of the adequacy of hematologic variables and Cbl concentrations as measures of Cbl status. 36 We also were interested in exploring less intense dosing schedules for our patients, but when owners were asked whether they would consider every-otherday administration of PO Cbl, they declined. Reasons for a lack of interest included the low cost of the PO Cbl product and the impracticability of every-other-day dosing.
We did not measure serum Cbl concentrations routinely because long-term experience has shown that low or even undetectable serum
Cbl concentrations often are encountered in clinically healthy Border
Collies and Beagles that have received parenteral treatment for IGS. 13, 16 This finding also has been reported in clinically healthy Bor- der Collies, Beagles, and Giant Schnauzers that were receiving longterm Cbl supplementation for IGS. 7, 13, 15, 16, 18 The results of our previous study on parenteral Cbl supplementation supported this finding with the majority of serum Cbl concentrations (22 of 24 samples) being below the RI (11) or even undetectable (11) in the face of low MMA concentrations. 13 We speculated that the half-life of Cbl bound intracellularly as a coenzyme is longer than the residence time of Cbl in the circulation, which would mean that Cbl continues to be active in tissues and Cbl-dependent metabolism remains normal even when serum concentrations are low. Interestingly, the few available serum
Cbl concentrations in this study were all within RI, similar to what has been published recently. 25, 26 Urine MMA results from dog 1 stood out insofar as they initially remained higher than those of dogs 2 and 3. Urine MMA concentrations at t1-t6 were in agreement with those of a previous study when Dog 1 was treated with monthly and bimonthly parenteral Cbl supplementation ( Figure 1) . 13 In contrast, concurrent evaluation of serum MMA concentrations (t1, t5-t10) showed that all results were within the RI (Figure 1 ), a finding that had also been previously noted in this dog during parenteral (bimonthly) Cbl supplementation. 13 At that time, quate Cbl supplementation when compared to published RIs. 41 We had previously been working with a homocysteine RI of 4.3-18.4 μmol/L that was established using HPLC and fluorometric detection in 35 dogs. 27 Because of laboratory and methodology changes, we currently do not have an in-house homocysteine RI. A homocysteine RI of 5-22.1 μmol/L recently was established using a gas chromatography-mass spectrometry (GC-MS) method in 35 healthy dogs. 41 Most homocysteine concentrations in dog 1 were within this RI, whereas 2 of 9 measurements, over the 13-month period of PO supplementation were minimally higher. In this regard, Cbl supplementation biweekly 9 and once in a Giant Schnauzer 4 weeks after IM (1 mg) Cbl supplementation. 18 Clearly, the value of homocysteine as a therapeutic marker in dogs with IGS requires further study.
The main limitation of our study is the small number of dogs;
however, we were dependent on the willingness of pet owners to cooperate. We are working with several Border Collies and Beagles with IGS that are doing very well clinically with daily PO Cbl supplementation but unfortunately do not have a complete data set to publish these cases. The situation is similar in humans when considering the ratio of treatment studies 36, 38 to disease prevalence of IGS.
In conclusion, a maintenance dose of 1 mg cyano-Cbl adminis- 
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